Business
C4 Therapeutics is a clinical-stage biopharmaceutical company using its TORPEDO platform to design small-molecule protein degraders.
C4 Therapeutics held FY2025 revenue roughly flat and trimmed its net loss, but FCF burn worsened and insiders did not buy.
The read at a glance✓ Audited against SEC data
- Business mix — Targeted protein degradationNote
- Revenue — $35.9M, +1.0%Note
- Net income — ($105.0M), lossWatch
- FCF — ($99.3M), worseWatch
- Equity — $256.6M, +18.8%OK
- Insiders — 0 purchases and 1 saleWatch
- Accounting — Altman weak; Beneish clean; EQ greyWatch
Leadership changes
From C4 Therapeutics, Inc.'s own filings, the day they're filed.
- Mark Mossler · Chief Accounting Officer · departureeff. 2026-05-15
- Bruce Downey · Directors · departureeff. 2025-04-10
- Stewart Fisher · Chief Scientific Officer · departureeff. 2024-10-01
Latest filings
- 8-K · Company announcement2026-08-11
- 10-Q · Quarterly report2026-08-11
- 8-K · Company announcement2026-06-24
- 8-K · Company announcement2026-06-11
- 8-K · Company announcement2026-05-15
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about C4 Therapeutics, Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.